Awakn Life Sciences Announces Upsizing and Closing of Tranche of Private Placement Financing

Rhea-AI Summary

Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) has announced an upsizing of its non-brokered private placement financing from $1,000,000 to $2,000,000. The company has closed a fourth tranche of the offering, issuing 857,143 units at $0.46 per unit, raising an additional $394,286 for a combined total of $1,117,142. Each unit consists of one common share and 0.75 of a warrant, with each whole warrant allowing the purchase of one common share at $0.63 for five years. The proceeds will be used for general working capital. Securities issued are subject to a four-month hold period and applicable resale rules.

Positive

• Successful upsizing of private placement from $1,000,000 to $2,000,000, indicating strong investor interest
• Closing of fourth tranche raising $394,286, bringing total raised to $1,117,142
• Warrants provide potential for additional future funding at $0.63 per share

Negative

• Dilution of existing shareholders' ownership due to issuance of new shares
• Potential future dilution if warrants are exercised

Toronto, Ontario--(Newsfile Corp. - September 18, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company") a clinical-stage biotechnology company developing therapeutics for substance use and mental health disorders, with a near-term focus on Alcohol Use Disorder ("AUD"), is pleased to announce that, further to its press releases dated April 3, 2024, April 17, 2024, June 4, 2024 and July 31, 2024, it has determined to increase the size of its previously announced non-brokered private placement financing (the "Offering") from up to $1,000,000 to up to $2,000,000. Additionally, Awakn is pleased to announce the closing of a fourth tranche of the Offering through the issuance of an additional 857,143 units (the "Units") at a price of $0.46 per Unit for additional gross proceeds of $394,286 for a combined total of $1,117,142.

Each unit is comprised of one common share in the capital of the Company (each, a "Common Share") and three quarters (0.75) of one whole Common Share purchase warrant (each whole warrant, a "Warrant"). Each Warrant entitles the holder thereof to acquire one Common Share at a price of $0.63 per Common Share for a period of five (5) years from the date of issuance. Gross proceeds from the Offering will be used to fund the company's general working capital.

All securities issued in connection with the Offering will be subject to a hold period of four months plus a day from the date of issuance and the resale rules of applicable securities legislation.

This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons as defined under applicable United States securities laws unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

About Awakn Life Sciences Corp.

Awakn Life Sciences Corp. is a clinical-stage biotechnology company developing therapeutics targeting substance use and mental health disorders. Awakn has a near-term focus on AUD, a condition affecting approximately 29 million adults in the US and approximately 40 million in the US and key European markets for which the current standard of care is inadequate. Our goal is to provide breakthrough therapeutics to addiction sufferers in desperate need and our strategy is focused on commercialising our R&D pipeline across multiple channels.

www.awaknlifesciences.com | LinkedIn | X (formerly Twitter)

Notice Regarding Forward-Looking Information

This news release contains certain forward-looking information and forward-looking statements, as defined in applicable securities laws (collectively referred to herein as "forward-looking statements"). Forward-looking statements reflect current expectations or beliefs regarding future events or the Company's future performance. All statements other than statements of historical fact are forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "continues", "forecasts", "projects", "predicts", "intends", "anticipates", "targets" or "believes", or variations of, or the negatives of, such words and phrases or state that certain actions, events or results "may", "could", "would", "should", "might" or "will" be taken, occur or be achieved, including statements relating the business of the Company. All forward-looking statements, including those herein are qualified by this cautionary statement.

Although the Company believes that the expectations expressed in such statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the statements. There are certain factors that could cause actual results to differ materially from those in the forward-looking information. These include, but are not limited to: fluctuations in general macroeconomic conditions; the business plans and strategies of the Company; the ability of the Company to comply with all applicable governmental regulations in a highly regulated business; the inherent risks in investing in target companies or projects which have limited or no operating history and are engaged in activities currently considered illegal in some jurisdictions; changes in laws; limited operating history; reliance on management; requirements for additional financing; competition; fluctuations in securities markets; inconsistent public opinion and perception regarding the medical-use of psychedelic drugs; expectations regarding the size of the addiction market; and regulatory or political change. Readers are cautioned that the foregoing list of factors is not exhaustive of the factors that may affect forward-looking statements. Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release speak only as of the date of this news release or as of the date or dates specified in such statements.

Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking information. For more information on the Company, investors are encouraged to review the Company's public filings on SEDAR at www.sedar.com. The Company disclaims any intention or obligation to update or revise any forward- looking information, whether as a result of new information, future events or otherwise, other than as required by law.

Investor Enquiries:
Anthony Tennyson, CEO, Awakn Life Sciences
anthony.tennyson@awaknlifesciences.com
416-270-9566

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/223687

FAQ

How much did Awakn Life Sciences (AWKNF) raise in its latest private placement tranche?

Awakn Life Sciences raised $394,286 in its latest (fourth) tranche of the private placement offering.

What is the total amount raised by Awakn Life Sciences (AWKNF) in its private placement so far?

Awakn Life Sciences has raised a combined total of $1,117,142 in its private placement offering so far.

What is the price per unit in Awakn Life Sciences' (AWKNF) private placement?

The price per unit in Awakn Life Sciences' private placement is $0.46.

What are the terms of the warrants issued in Awakn Life Sciences' (AWKNF) private placement?

Each whole warrant allows the purchase of one common share at $0.63 for a period of five years from the date of issuance.